Abraham A Pinter

US Patent:

6815201, Nov 9, 2004

Filed:

Jan 2, 2002

Appl. No.:

10/038407

Inventors:

Abraham Pinter - Brooklyn NY

Assignee:

The Public Health Research Institute of the City of New York, Inc. - Newark NJ

International Classification:

C12N 516

US Classification:

4353391, 435 5, 435 6, 435 697, 5303873, 53038835

Abstract:

The invention features a protein which includes a gp120 V1/V2 domain of an HIV-1 strain and not a gp120 V3 domain of an HIV-1 strain, which protein does not substantially bind CD4. The gp120 V1/V2 domain of the protein displays an epitope which is recognized by an antibody which neutralizes at least one HIV-1 primary isolate with a ND of less than 100 g/ml.

US Patent:

8475799, Jul 2, 2013

Filed:

Aug 11, 2008

Appl. No.:

12/672585

Inventors:

Abraham Pinter - Brooklyn NY, US

Assignee:

University of Medicine and Dentistry of New Jersey - New Brunswick NJ

International Classification:

A61K 39/42
A61K 39/21
C07K 16/00

US Classification:

4241601, 4242081, 53038835

Abstract:

The invention relates to isolated monoclonal antibodies which specifically bind to the C-terminal heptad repeat region of gp41 (HR2) and neutralize an HIV-1 primary isolate.

US Patent:

20050058983, Mar 17, 2005

Filed:

Jul 25, 2003

Appl. No.:

10/628004

Inventors:

Abraham Pinter - Brooklyn NY, US
Yuxian He - Forest Hills NY, US
Jose Corvalan - Foster City CA, US

International Classification:

C12Q001/70

US Classification:

435005000, 530388300

Abstract:

The present invention relates to a novel human antibody, and antigen-binding portion thereof, that specifically binds HIV-1 gp120 protein and that has HIV-1 neutralizing activity. The present invention also relates to a cell line that produces an antibody of this invention. The present invention further relates to a pharmaceutical composition or a kit comprising an antibody or antigen binding portion thereof of this invention. The present invention further relates to a method of using the antibody of this invention to treat a subject with an HIV-1 infection or prevent a subject from getting an HIV-1 infection. The present invention also relates to a novel method of making an antibody of this invention. The method involves using a non-human transgenic animal. The present invention further relates to methods of identifying regions of gp120 for use as HIV-1 vaccine.

US Patent:

20090098144, Apr 16, 2009

Filed:

Aug 20, 2008

Appl. No.:

12/195318

Inventors:

Susan ZOLLA-PAZNER - New York NY, US
Miroslaw K. Gorny - Harrison NY, US
Timothy J. Cardozo - New York NY, US
Ruben Abagyan - La Jolla CA, US
Maxim Totrov - San Diego CA, US
Shan Lu - Franklin MA, US
Abraham Pinter - Brooklyn NY, US

Assignee:

New York University - New York NY
Molsoft LLC - La Jolla CA
University of Massachusetts - Boston MA
University of Medicine and Dentistry of New Jersey - Newark NJ

International Classification:

A61K 39/42
C07K 16/10
A61P 31/18

US Classification:

4241601, 5303894

Abstract:

Insertion of HIV-1 V3 loop peptides from the viral glycoprotein gp120 into selected, immunogenic scaffold proteins results in a recombinant polypeptide that is a potent V3 immunogen. V3 immunogens include natural and consensus V3 sequences and cyclic and reverse peptides. Preferred scaffold proteins are Cholera Toxin subunit B and homologues thereof including closely related enterotoxins. Such immunogenic polypeptides induce broadly reactive anti-gp120 antibodies specific for V3 epitopes that can neutralize heterologous HIV-1 subtypes and strains. These polypeptide, methods for preparing them, and methods for inducing anti-gp120 (V3-specific) antibody) responses using them are disclosed.

US Patent:

20110311569, Dec 22, 2011

Filed:

Jul 10, 2007

Appl. No.:

12/309256

Inventors:

Abraham Pinter - Brooklyn NY, US

International Classification:

A61K 39/21
C07K 7/06
C07K 9/00
A61P 31/18
C12N 15/49
C12N 15/63
C12N 7/06
A61P 37/04
C07K 14/16
C07K 16/10

US Classification:

4241881, 530324, 530329, 530350, 530322, 5303879, 536 2372, 4353201, 435238

Abstract:

This invention features polypeptides, variants thereof, and fragments thereof useful in eliciting an immune response (e.g., neutralizing antibodies) against abroad spectrum of HIV-I isolates. The polypeptides, variants, and fragments include a portion of the gp120 V2 domain of HIV-I. The polypeptides, variants, and fragments display an epitope that is recognized by at least one antibody which neutralizes at least one HIV-I primary isolate. This invention also features nucleic acid sequences encoding those polypeptides. In addition, the invention provides methods of screening for inhibitors of HIV-I entry into cells, as well as methods of treatment using the inhibitors.

US Patent:

20130287804, Oct 31, 2013

Filed:

Sep 28, 2011

Appl. No.:

13/876918

Inventors:

Timothy Cardozo - New York NY, US
Susan Zolla-Pazner - New York NY, US
Abraham Pinter - New York NY, US
Chavdar Krachmarov - Livingston NJ, US
Shan Lu - Franklin MA, US
Shixia Wang - Northborough MA, US
Maxim Totrov - San Diego CA, US

Assignee:

NEW YORK UNIVERSITY - New York NY
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY - Newark NJ
UNIVERSITY OF MASSACHUSETTS - Boston MA
MOLSOFT LLC - San Diego CA

International Classification:

C07K 14/00

US Classification:

4241851, 530350, 530327, 435 72, 435 5

Abstract:

The present invention is directed to a recombinant immunogenic polypeptide. The polypeptide includes a loop peptide inserted into an immunogenic scaffold protein. The loop polypeptide has an amino acid sequence which presents the 3074 mAb- or the 2219/2557 mAb-targeted epitope of the HIV gp120 protein and not other known epitopes of the HIV gp120 protein. When used as an immunogen, the polypeptide induces an antibody response which neutralizes heterologous HIV-1 viruses in a pattern similar to that observed for the 3074 mAb- or the 2219/2557 mAb-targeted epitope, respectively. Pharmaceutical compositions containing the immunogenic polypeptide as well as methods of making and using it are also disclosed.

US Patent:

59223251, Jul 13, 1999

Filed:

May 22, 1995

Appl. No.:

8/447214

Inventors:

Shermaine A. Tilley - New York NY
Abraham Pinter - Brooklyn NY

Assignee:

Public Health Research Institute of the City of New York, Inc. - New York NY

International Classification:

A61K 3921
C12P 2104
C12P 2108

US Classification:

4242081

Abstract:

A synergistic combination of antibodies specific for HIV envelope glycoprotein gp120 is described. One of the antibodies specific for the V3 loop and the other is specific for the CD-4 binding site of gp120.

US Patent:

44068859, Sep 27, 1983

Filed:

Dec 28, 1978

Appl. No.:

5/973958

Inventors:

Abraham Pinter - Brooklyn NY

Assignee:

Research Corporation - New York NY

International Classification:

A61K 3912
A61K 3702

US Classification:

424 88

Abstract:

Non-denatured [gp90] is isolated from oncornavirus envelopes including feline and murine leukemia virus envelopes and utilized as vaccines. The materials as isolated may be used directly on in various compositions.

Author:

Abraham Pinter

ISBN #:

0123225701